Histrelin implant for the treatment of central precocious puberty

Samar Rahhal, Erica Eugster

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Central precocious puberty is defined as puberty occurring prior to the age of 7.5-8 years in girls and 9 years in boys. The main goals of treatment include the arrest of pubertal progression and preservation of final adult height. In the USA, depot leuprolide has been the mainstay of treatment. It is a gonadotropin-releasing hormone agonist that is administered as an intramuscular injection every 4 weeks. Recently, a 1-year subcutaneous implant has been developed for continuous delivery of the gonadotropin-releasing hormone agonist histrelin. Initial prospective trials have demonstrated that it is efficacious, safe and well tolerated. It is an exciting alternative to painful monthly injections for the treatment of central precocious puberty.

Original languageEnglish
Pages (from-to)141-145
Number of pages5
JournalPediatric Health
Volume2
Issue number2
DOIs
StatePublished - Apr 2008

Fingerprint

Gonadotropin-Releasing Hormone
Leuprolide
Intramuscular Injections
Puberty
Therapeutics
Injections
Central Precocious Puberty
histrelin

Keywords

  • Central precocious puberty
  • Gonadotropin-releasing hormone agonists
  • Histrelin
  • Implant

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pediatrics

Cite this

Histrelin implant for the treatment of central precocious puberty. / Rahhal, Samar; Eugster, Erica.

In: Pediatric Health, Vol. 2, No. 2, 04.2008, p. 141-145.

Research output: Contribution to journalArticle

@article{38fd5032b89041358112cd4d6a0ff2fe,
title = "Histrelin implant for the treatment of central precocious puberty",
abstract = "Central precocious puberty is defined as puberty occurring prior to the age of 7.5-8 years in girls and 9 years in boys. The main goals of treatment include the arrest of pubertal progression and preservation of final adult height. In the USA, depot leuprolide has been the mainstay of treatment. It is a gonadotropin-releasing hormone agonist that is administered as an intramuscular injection every 4 weeks. Recently, a 1-year subcutaneous implant has been developed for continuous delivery of the gonadotropin-releasing hormone agonist histrelin. Initial prospective trials have demonstrated that it is efficacious, safe and well tolerated. It is an exciting alternative to painful monthly injections for the treatment of central precocious puberty.",
keywords = "Central precocious puberty, Gonadotropin-releasing hormone agonists, Histrelin, Implant",
author = "Samar Rahhal and Erica Eugster",
year = "2008",
month = "4",
doi = "10.2217/17455111.2.2.141",
language = "English",
volume = "2",
pages = "141--145",
journal = "Pediatric Health",
issn = "1745-5111",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Histrelin implant for the treatment of central precocious puberty

AU - Rahhal, Samar

AU - Eugster, Erica

PY - 2008/4

Y1 - 2008/4

N2 - Central precocious puberty is defined as puberty occurring prior to the age of 7.5-8 years in girls and 9 years in boys. The main goals of treatment include the arrest of pubertal progression and preservation of final adult height. In the USA, depot leuprolide has been the mainstay of treatment. It is a gonadotropin-releasing hormone agonist that is administered as an intramuscular injection every 4 weeks. Recently, a 1-year subcutaneous implant has been developed for continuous delivery of the gonadotropin-releasing hormone agonist histrelin. Initial prospective trials have demonstrated that it is efficacious, safe and well tolerated. It is an exciting alternative to painful monthly injections for the treatment of central precocious puberty.

AB - Central precocious puberty is defined as puberty occurring prior to the age of 7.5-8 years in girls and 9 years in boys. The main goals of treatment include the arrest of pubertal progression and preservation of final adult height. In the USA, depot leuprolide has been the mainstay of treatment. It is a gonadotropin-releasing hormone agonist that is administered as an intramuscular injection every 4 weeks. Recently, a 1-year subcutaneous implant has been developed for continuous delivery of the gonadotropin-releasing hormone agonist histrelin. Initial prospective trials have demonstrated that it is efficacious, safe and well tolerated. It is an exciting alternative to painful monthly injections for the treatment of central precocious puberty.

KW - Central precocious puberty

KW - Gonadotropin-releasing hormone agonists

KW - Histrelin

KW - Implant

UR - http://www.scopus.com/inward/record.url?scp=45149130570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45149130570&partnerID=8YFLogxK

U2 - 10.2217/17455111.2.2.141

DO - 10.2217/17455111.2.2.141

M3 - Article

AN - SCOPUS:45149130570

VL - 2

SP - 141

EP - 145

JO - Pediatric Health

JF - Pediatric Health

SN - 1745-5111

IS - 2

ER -